Peripheral Blood Biomarkers Associated with Clinical Outcome in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
Open Access
- 20 November 2017
- journal article
- research article
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 13 (1), 97-105
- https://doi.org/10.1016/j.jtho.2017.10.030
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Eosinophils and CancerCancer Immunology Research, 2014
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survivalAnnals Of Oncology, 2013
- Coordinated regulation of myeloid cells by tumoursNature Reviews Immunology, 2012
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use settingCancer, 2010
- Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03European Journal Of Cancer, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- A systematic review of the association between circulating concentrations of C reactive protein and cancerJournal of Epidemiology and Community Health, 2007
- Pretreatment Levels of Peripheral Neutrophils and Leukocytes As Independent Predictors of Overall Survival in Patients With American Joint Committee on Cancer Stage IV Melanoma: Results of the EORTC 18951 Biochemotherapy TrialJournal of Clinical Oncology, 2007
- Regulation of Carcinogenesis by IL-5 and CCL11: A Potential Role for Eosinophils in Tumor Immune SurveillanceThe Journal of Immunology, 2007